fda compounding semaglutide enforcement november 2025 Novo Nordisk expands legal action to protect US patients from unsafe, non- FDA-approved compounded "semaglutide" Compounded "semaglutide" is not FDA-approved

Burgess E, Hassmn P, Welvaert M, Pumpa KL

According to company phase III clinical trial data, patients using oral Wegovy lost approximately 14% of their body weight when combined with reduced-calorie diet and exercise

Understanding whether tirzepatide burns fat or just suppresses appetite and whether tirzepatide increases metabolism helps calibrate realistic expectations about the mechanism

2025 Jan;87(1):159-169

Phase 2 trials showed up to 24% body weight reduction the highest observed for any obesity compound to date positioning it as the frontier compound in metabolic research

CagriSema looks more familiar and potentially easier to contextualize because it builds on semaglutide plus amylin